<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>Operator_BCSC1819_S12_C00FM_pi-xviii_2P</title>
		<link href="Operator_BCSC1819_S12_C00FM_pi-xviii_2P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="Operator_BCSC1819_S12_C00FM_pi-xviii_2P" lang="en-US">
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer000" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="Operator_BCSC1819_S12_C00FM_pi-xviii_2P-web-resources/image/AAO_med_full_clr_c_cmyk_reg.png" alt="" />
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="Operator_BCSC1819_S12_C00FM_pi-xviii_2P-web-resources/image/AAO_tag_gray_c_cmyk_reg.png" alt="" />
			</div>
		</div>
		<div id="_idContainer002" class="Basic-Text-Frame">
			<p class="NEW-Title"><span class="CharOverride-1">Retina and Vitreous</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer003" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer004" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
			</div>
		</div>
		<div id="_idContainer005" class="Basic-Graphics-Frame _idGenObjectStyleOverride-1">
			<p class="BCSC-Spelled-Out---Cover ParaOverride-1"><span class="CharOverride-2"> </span><span class="CharOverride-3">BCSC</span></p>
			<p class="BCSC-Spelled-Out---Cover"><span class="CharOverride-4"> </span><span class="CharOverride-4">Basic and Clinical</span></p>
			<p class="BCSC-Spelled-Out---Cover"><span class="CharOverride-4"> </span><span class="CharOverride-4">Science Course</span><span class="CharOverride-5">™</span></p>
		</div>
		<div id="_idContainer006" class="Basic-Text-Frame">
			<p class="Year---Cover ParaOverride-2"><span class="CharOverride-6">2018–2019</span></p>
		</div>
		<div id="_idContainer007" class="Basic-Text-Frame">
			<p class="Basic-Paragraph ParaOverride-2"><span class="CharOverride-7">Funded in part by the Educational Trust </span></p>
			<p class="Basic-Paragraph ParaOverride-2"><span class="CharOverride-7">Fund/Retina Research Foundation</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="data:image/jpg;base64,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" alt="" />
			</div>
		</div>
		<div id="_idContainer009" class="Basic-Text-Frame">
			<p class="Basic-Paragraph ParaOverride-3"><span class="CharOverride-8">12</span></p>
		</div>
		<div id="_idContainer010" class="Basic-Text-Frame">
			<p class="fm-tp--pub-rev-date-"><span class="CharOverride-9">Published after collaborative <br />review with the European Board <br />of Ophthalmology subcommittee</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer011" class="_idGenObjectStyleOverride-3">
			</div>
		</div>
		<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-copyright-cme-text ParaOverride-4">The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.</p>
			<p class="fm-only_fm-copyright-cme-text ParaOverride-5">The American Academy of Ophthalmology designates this enduring material for a maximum of 15 <span class="CharOverride-10">AMA PRA Category 1 Credits</span><span class="CharOverride-11">™</span>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.</p>
			<p class="fm-only_fm-copyright-text">CME expiration date: June 1, 2021. <span class="CharOverride-10">AMA PRA Category 1 Credits</span><span class="CharOverride-11">™</span> may be claimed only once between June 1, 2018, and the expiration date.</p>
			<p class="fm-only_fm-copyright-text">BCSC<span class="CharOverride-11">®</span> volumes are designed to increase the physician’s ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.</p>
			<p class="fm-only_fm-copyright-text">To claim <span class="CharOverride-10">AMA PRA Category 1 Credits</span><span class="CharOverride-11">™</span> upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 12 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.</p>
			<p class="fm-only_fm-copyright-text">The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician’s own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers’ package inserts or other independent sources, and considered in light of the patient’s condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. <span class="CharOverride-12">The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law.</span> The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.</p>
			<p class="fm-only_fm-copyright-text">AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Femtocenter, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, <span class="italic">Ophthalmology,</span> <span class="italic">Ophthalmology Retina, </span>Preferred Practice Pattern, ProVision, The Ophthalmic News &amp; Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.</p>
			<p class="fm-only_fm-copyright-text ParaOverride-6"><span class="CharOverride-13">Cover image: </span>End-stage chorioretinal atrophy in pathologic myopia. <span class="italic">(Courtesy of Richard F. </span><span class="italic">Spaide, MD.)</span></p>
			<p class="fm-only_fm-title _idGenParaOverride-1">Basic and Clinical Science Course</p>
			<p class="fm-only_fm-contributors-text">Louis B. Cantor, MD, Indianapolis, Indiana, <span class="CharOverride-10">Senior Secretary for Clinical Education</span></p>
			<p class="fm-only_fm-contributors-text">Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, <span class="CharOverride-10">Secretary for Lifelong Learning and Assessment</span></p>
			<p class="fm-only_fm-contributors-text">George A. Cioffi, MD, New York, New York, <span class="CharOverride-10">BCSC Course Chair</span></p>
			<p class="fm-only_fm-h1">Section 12</p>
			<p class="fm-only_fm-h2 ParaOverride-7">Faculty</p>
			<p class="fm-only_fm-contributors-text">Colin A. McCannel, MD, <span class="CharOverride-10">Chair,</span> Los Angeles, California</p>
			<p class="fm-only_fm-contributors-text">Audina M. Berrocal, MD, Miami, Florida </p>
			<p class="fm-only_fm-contributors-text">Graham E. Holder, PhD, London, United Kingdom </p>
			<p class="fm-only_fm-contributors-text">Stephen J. Kim, MD, Nashville, Tennessee</p>
			<p class="fm-only_fm-contributors-text">Brian C. Leonard, MD, Ottawa, Canada </p>
			<p class="fm-only_fm-contributors-text">Richard B. Rosen, MD, New York, New York</p>
			<p class="fm-only_fm-contributors-text">Richard F. Spaide, MD, New York, New York </p>
			<p class="fm-only_fm-contributors-text">Jennifer K. Sun, MD, MPH, Boston, Massachusetts</p>
			<p class="fm-only_fm-disclaimers">The Academy wishes to acknowledge the <span class="italic">American Society of Retina Specialists (ASRS),</span> the <span class="italic">Macula Society,</span> and the <span class="italic">Retina Society</span> for recommending faculty members to the BCSC Section 12 committee. </p>
			<p class="fm-only_fm-disclaimers">The Academy also wishes to acknowledge the following committees for review of this edition: </p>
			<p class="fm-only_fm-disclaimers"><span class="CharOverride-10">Committee on Aging: </span>Amy C. Shefler, MD, Houston, Texas</p>
			<p class="fm-only_fm-disclaimers"><span class="CharOverride-10">Vision Rehabilitation Committee:</span> William M. McLaughlin Jr, DO, Allentown, Pennsylvania</p>
			<p class="fm-only_fm-disclaimers"><span class="CharOverride-10">Practicing Ophthalmologists Advisory Committee for Education: </span>David J. Browning, MD, PhD, <span class="CharOverride-10">Primary Reviewer,</span> Charlotte, North Carolina; Edward K. Isbey III, MD, <span class="CharOverride-10">Chair,</span> Asheville, North Carolina; Alice Bashinsky, MD, Asheville, North Carolina; Bradley D. Fouraker, MD, Tampa, Florida; Steven J. Grosser, MD, Golden Valley, Minnesota; &#173;Stephen&#160;R. Klapper, MD, Carmel, Indiana; James A. Savage, MD, Memphis, Tennessee; Michelle S. Ying, MD, Ladson, South Carolina</p>
			<p class="fm-only_fm-disclaimers">The Acad&#173;emy also wishes to acknowledge the following committee for assistance in developing study questions and answers for this BCSC Section:</p>
			<p class="fm-only_fm-disclaimers"><span class="italic">Self-&#173;Assessment Committee:</span> Stephen&#160;R. Russell, MD, Iowa City, Iowa; Paul&#160;B. Griggs, MD, Seattle, Washington; Rachel&#160;M. Huckfeldt, MD, Boston, Mas&#173;sa&#173;chu&#173;setts; Ravi&#160;S.&#160;J. Singh, MD, Shawnee Mission, Kansas</p>
			<p class="fm-only_fm-disclaimers">In addition, the Acad&#173;emy wishes to recognize the impor&#173;tant contributions of Michael&#160;B. Gorin, MD, PhD, in the development of Chapter 13.</p>
			<p class="fm-only_fm-disclaimers ParaOverride-8"><img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" /></p>
			<p class="fm-only_fm-disclaimers ParaOverride-9"><span class="CharOverride-10">European Board of Ophthalmology:</span> Catherine Creuzot-Garcher, MD, PhD, <span class="italic">EBO Chair,</span> Dijon, France; Peter J. Ringens, MD, PhD, <span class="italic">EBO Liaison,</span> Maastricht, Netherlands; Anat Loewenstein, MD, Tel Aviv-Yafo, Israel; Pascale G. Massin, MD, Paris, France; Edoardo Midena, MD, Padua, Italy; Ramin Tadayoni, MD, PhD, Paris, France; Sebastian Wolf, MD,&#160;PhD, Bern, Switzerland</p>
			<p class="fm-only_fm-h2">Financial Disclosures</p>
			<p class="fm-only_fm-disclaimers ParaOverride-9">Academy staff members who contributed to the development of this product state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.</p>
			<p class="fm-only_fm-disclaimers">The authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had the following financial relationships:<span class="CharOverride-14">*</span></p>
			<p class="fm-only_fm-disclaimers">Dr Berrocal: Alcon (C), Allergan (C), Bausch + Lomb (C), Bayer HealthCare Phar&#173;ma&#173;ceu&#173;ti&#173;cals (L), DORC Dutch Ophthalmic Research Center (International)/Dutch Ophthalmic USA (L), Visunex Medical Systems (C)</p>
			<p class="fm-only_fm-disclaimers">Dr Browning: Aerpio Therapeutics (S), Alcon (S), Alimera Sciences (C), Genentech (S), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (S), Ohr Phar&#173;ma&#173;ceu&#173;ti&#173;cal (S), Pfizer (S), Regeneron Phar&#173;ma&#173;ceu&#173;ti&#173;cals (S), ZEISS (O)</p>
			<p class="fm-only_fm-disclaimers">Dr Creuzot-&#173;Garcher: Allergan (C, L), Bausch + Lomb (C, L), Bayer (C, L), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C, L, S), Roche (C), Théa (C, S)</p>
			<p class="fm-only_fm-disclaimers">Dr Fouraker: Addition Technology (C, L), Alcon (C, L), KeraVision (C, L), OASIS Medical (C, L)</p>
			<p class="fm-only_fm-disclaimers">Dr Gorin: University of Pittsburgh (P); University of California, Los Angeles (P)</p>
			<p class="fm-only_fm-disclaimers">Dr Grosser: Injectsense (O), Ivantis (O)</p>
			<p class="fm-only_fm-disclaimers">Dr Holder: Isarna Therapeutics (C), Roche (C), Servier Laboratories (C)</p>
			<p class="fm-only_fm-disclaimers">Dr Huckfeldt: Applied Ge&#173;ne&#173;tic Technologies Corporation (S), Spark Therapeutics (S)</p>
			<p class="fm-only_fm-disclaimers">Dr Isbey: Alcon (S), Allscripts (C), Bausch + Lomb (S), Medflow (C), Oculos Clinical &#173;Research (S)</p>
			<p class="fm-only_fm-disclaimers">Dr Klapper: AdOM Advanced Optical Technologies (O)</p>
			<p class="fm-only_fm-disclaimers">Dr Leonard: Abbott Medical Optics (S), Alcon (S), Allergan (S), Annidis (O), Bausch + Lomb (S), Bayer HealthCare Phar&#173;ma&#173;ceu&#173;ti&#173;cals (S), Johnson &amp; Johnson Vision (S), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (S), Ophthalmic Direct (S), Shire (S)</p>
			<p class="fm-only_fm-disclaimers">Dr Loewenstein: Alcon (C), Allergan (C, L), Bayer (C, L), ForSight Labs (C), Notal Vision (C), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C, L)</p>
			<p class="fm-only_fm-disclaimers">Dr Massin: Allergan (C, L), Bayer (C), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C, L)</p>
			<p class="fm-only_fm-disclaimers">Dr McCannel: DORC Dutch Ophthalmic Research Center (International)/Dutch Ophthalmic USA (C, L), Genentech (S), Insight Instruments (C), Santen Phar&#173;ma&#173;ceu&#173;ti&#173;cal (C)</p>
			<p class="fm-only_fm-disclaimers">Dr Rosen: Allergan (S), Boehringer Ingelheim (C), cellVIEW (C), Clarity Medical Systems (C), Genentech (S), Glauco-&#173;Health (C), Guardion Health Sciences (C), Nano Ret&#173;ina (C), Ocata Therapeutics (C), OD-&#173;OS (C), Opticology (O), Optovue (C, P), Regeneron Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C)</p>
			<p class="fm-only_fm-disclaimers">Dr Russell: Acucela (S), IDx (O), Spark Therapeutics (C, S), University of Iowa (P)</p>
			<p class="fm-only_fm-disclaimers">Dr Shefler: Allergan (C), Aura Biosciences (S), Genentech (S), Regeneron Phar&#173;ma&#173;ceu&#173;ti&#173;cals (S)</p>
			<p class="fm-only_fm-disclaimers">Dr Spaide: Bausch + Lomb (C), Genentech (C), Topcon Medical Systems (C, P)</p>
			<p class="fm-only_fm-disclaimers">Dr Sun: Adaptive Sensory Technology (S), Allergan (C), Bayer HealthCare Phar&#173;ma&#173;ceu&#173;ti&#173;cals (L), Boston Micromachines Corporation (S), Eleven Biotherapeutics (C), Genentech (S), KalVista Phar&#173;ma&#173;ceu&#173;ti&#173;cals (S), Merck &amp; Co. (C), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C), Op&#173;tovue (S), Regeneron Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C)</p>
			<p class="fm-only_fm-disclaimers">Dr Tadayoni: Alcon (C, L, S), Alimera Sciences (C, L), Allergan (C, L, S), Bausch + Lomb (C, L), Bayer HealthCare Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C, L), Genentech (C), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C, L, S), ThromboGenics (C), ZEISS (C, L)</p>
			<p class="fm-only_fm-disclaimers">Dr Wolf: Alcon (C), Allergan (C), Bayer HealthCare Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C, L, S), Heidelberg Engineering (C, S), Novartis Phar&#173;ma&#173;ceu&#173;ti&#173;cals (C, S), Optos (S), Roche (C)</p>
			<p class="fm-only_fm-disclaimers">The other authors and reviewers state that within the 12 months prior to their contributions to this CME activity and for the duration of development, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.</p>
			<p class="fm-only_fm-disclaimers-footnote"><span class="CharOverride-14">*</span>C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/&#173;stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation</p>
			<p class="fm-only_fm-h2">Recent Past Faculty</p>
			<p class="fm-only_fm-contributors-text">Neal H. Atebara, MD</p>
			<p class="fm-only_fm-contributors-text">Emmett Cunningham Jr, MD, PhD, MPH</p>
			<p class="fm-only_fm-contributors-text">David Sarraf, MD</p>
			<p class="fm-only_fm-acknowledgments-text">In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.</p>
			<p class="fm-only_fm-h2">American Academy of Ophthalmology Staff</p>
			<p class="fm-only_fm-contributors-text">Dale E. Fajardo, EdD, MBA, <span class="CharOverride-10">Vice President, Education</span></p>
			<p class="fm-only_fm-contributors-text">Beth Wilson, <span class="CharOverride-10">Director, Continuing Professional Development</span></p>
			<p class="fm-only_fm-contributors-text">Ann McGuire, <span class="CharOverride-10">Acquisitions and Development Manager</span></p>
			<p class="fm-only_fm-contributors-text">Stephanie Tanaka, <span class="CharOverride-10">Publications Manager</span></p>
			<p class="fm-only_fm-contributors-text">D. Jean Ray, <span class="CharOverride-10">Production Manager</span></p>
			<p class="fm-only_fm-contributors-text">Susan Malloy, <span class="italic">Acquisitions Editor and Program Manager</span></p>
			<p class="fm-only_fm-contributors-text">Jasmine Chen, <span class="italic">Manager of E-Learning</span></p>
			<p class="fm-only_fm-contributors-text">Beth Collins, <span class="CharOverride-10">Medical Editor</span></p>
			<p class="fm-only_fm-contributors-text">Eric Gerdes,<span class="italic"> Interactive Designer</span></p>
			<p class="fm-only_fm-contributors-text _idGenParaOverride-1">Naomi Ruiz, <span class="CharOverride-10">Publications Specialist</span></p>
			<p class="fm-only_fm-title _idGenParaOverride-1">General Introduction</p>
			<p class="body-text--no-indent-">The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.</p>
			<p class="body-text">The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.</p>
			<p class="fm-only_fm-h2">Organization of the Course</p>
			<p class="body-text--no-indent-">The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:</p>
			<p class="fm-only_fm-numbered-list-first">&#9;1&#9;Update on General Medicine</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;2&#9;Fundamentals and Principles of Ophthalmology</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;3&#9;Clinical Optics</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;4&#9;Ophthalmic Pathology and Intraocular Tumors</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;5&#9;Neuro-Ophthalmology</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;6&#9;Pediatric Ophthalmology and Strabismus</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;7&#9;Orbit, Eyelids, and Lacrimal System</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;8&#9;External Disease and Cornea</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;9&#9;Intraocular Inflammation and Uveitis</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;10&#9;Glaucoma</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;11&#9;Lens and Cataract</p>
			<p class="fm-only_fm-numbered-list-mid">&#9;12&#9;Retina and Vitreous</p>
			<p class="fm-only_fm-numbered-list-last">&#9;13&#9;Refractive Surgery</p>
			<p class="body-text--no-indent-">In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.</p>
			<p class="fm-only_fm-h2">References</p>
			<p class="body-text--no-indent-">Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book. These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.</p>
			<p class="fm-only_fm-h2">Multimedia</p>
			<p class="body-text--no-indent-">This edition of Section 12, <span class="italic">Retina and Vitreous,</span> includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty to present important topics that are best delivered visually. This edition also includes interactive features, or &#173;“activities,” developed by members of the BCSC faculty. Both the videos and the activities are&#160;available to readers of the print and electronic versions of Section 12 (www.aao.org/bcscvideo_section12 and www.aao.org/bcscactivity_section12). Mobile-device users can scan the QR codes below (a QR-code reader must already be installed on the device) to access the videos and activities.</p>
			<p class="body-text--no-indent- ParaOverride-10"><img class="_idGenObjectAttribute-3" src="Operator_BCSC1819_S12_C00FM_pi-xviii_2P-web-resources/image/qrcode_S12-activity-landing.jpg" alt="" /></p>
			<p class="fm-only_fm-h2 ParaOverride-11">Self-Assessment and CME Credit</p>
			<p class="body-text--no-indent-">Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.</p>
			<p class="body-text">This Section of the BCSC has been approved by the American Board of Ophthalmology as a Maintenance of Certification Part II self-assessment and CME activity.</p>
			<p class="fm-only_fm-h2">Conclusion</p>
			<p class="body-text--no-indent-">The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.</p>
			<p class="body-text">The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.</p>
			<p class="body-text">The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.</p>
		</div>
		<div id="_idContainer015" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-copyright1--pub-info- ParaOverride-12">Copyright © 2018 American Academy of Ophthalmology. All rights reserved. No part of this publication may be reproduced without written permission. </p>
			<p class="fm-only_fm-copyright1--pub-info- ParaOverride-12">Printed in the United States of America.</p>
		</div>
		<div id="_idContainer016" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-copyright2--pub-info-">American Academy of Ophthalmology</p>
			<p class="fm-only_fm-copyright2--pub-info-">655 Beach Street</p>
			<p class="fm-only_fm-copyright2--pub-info-">Box 7424</p>
			<p class="fm-only_fm-copyright2--pub-info-">San Francisco, CA 94120-7424</p>
		</div>
		<div id="_idContainer017" class="_idGenObjectStyleOverride-1">
			<p class="fm-only_fm-title _idGenParaOverride-1">Contents</p>
			<p class="fm-only_fm-toc-fm1">General Introduction&#9;xvii</p>
			<p class="fm-only_fm-toc-fm2">Objectives<span class="fm-toc--leader-dots-">&#9;</span>1</p>
			<p class="fm-only_fm-toc-fm2 ParaOverride-9">Introduction<span class="fm-toc--leader-dots-">&#9;</span>3</p>
			<p class="fm-only_fm-toc01"><span class="fm-toc01--part-">Part I </span>Fundamentals and Diagnostic <br />Approaches<span class="fm-toc--leader-dots-">&#9;</span>5</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;1&#9;</span>Basic Anatomy<span class="fm-toc--leader-dots-">&#9;</span>7</p>
			<p class="fm-only_fm-toc03">The Vitreous&#9;7</p>
			<p class="fm-only_fm-toc03">Neurosensory Ret&#173;ina&#9;9</p>
			<p class="fm-only_fm-toc04">Ret&#173;i&#173;nal Topography&#9;9</p>
			<p class="fm-only_fm-toc04">Ret&#173;i&#173;nal Layers and Neurosensory Ele&#173;ments&#9;10</p>
			<p class="fm-only_fm-toc04">Ret&#173;i&#173;nal Vasculature and Oxygen Supply&#9;16</p>
			<p class="fm-only_fm-toc03">Ret&#173;i&#173;nal Pigment Epithelium&#9;17</p>
			<p class="fm-only_fm-toc03">Bruch Membrane&#9;19</p>
			<p class="fm-only_fm-toc03">Choroid&#9;19</p>
			<p class="fm-only_fm-toc03">Sclera&#9;20</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;2&#9;</span>Diagnostic Approach to Ret&#173;i&#173;nal Disease<span class="fm-toc--leader-dots-">&#9;</span>21</p>
			<p class="fm-only_fm-toc03">Ophthalmoscopy&#9;21</p>
			<p class="fm-only_fm-toc03">Imaging Technologies&#9;22</p>
			<p class="fm-only_fm-toc04">Fundus Camera Imaging&#9;22</p>
			<p class="fm-only_fm-toc04">Scanning &#173;Laser Ophthalmoscopy&#9;24</p>
			<p class="fm-only_fm-toc04">Optical Coherence Tomography&#9;25</p>
			<p class="fm-only_fm-toc04">Optical Coherence Tomography Angiography&#9;28</p>
			<p class="fm-only_fm-toc04">Fundus Autofluorescence&#9;29</p>
			<p class="fm-only_fm-toc04">Adaptive Optics Imaging&#9;33</p>
			<p class="fm-only_fm-toc04">Ret&#173;i&#173;nal Angiographic Techniques&#9;33</p>
			<p class="fm-only_fm-toc04">Ultrasonography&#9;39</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;3&#9;</span>Ret&#173;i&#173;nal Physiology and Psychophysics<span class="fm-toc--leader-dots-">&#9;</span>41</p>
			<p class="fm-only_fm-toc03">Electrophysiologic Testing&#9;41</p>
			<p class="fm-only_fm-toc03">Electroretinography&#9;42</p>
			<p class="fm-only_fm-toc04">Full-&#173;Field (Ganzfeld) ERG&#9;42</p>
			<p class="fm-only_fm-toc04">Multifocal ERG&#9;45</p>
			<p class="fm-only_fm-toc04">Pattern ERG&#9;45</p>
			<p class="fm-only_fm-toc04">Clinical Considerations&#9;46</p>
			<p class="fm-only_fm-toc03">Electro-&#173;oculography&#9;50</p>
			<p class="fm-only_fm-toc03">Visual Evoked Cortical Potentials&#9;52</p>
			<p class="fm-only_fm-toc03">Psychophysical Testing&#9;53</p>
			<p class="fm-only_fm-toc04">Color Vision&#9;54</p>
			<p class="fm-only_fm-toc04">Contrast Sensitivity&#9;56</p>
			<p class="fm-only_fm-toc04">Dark Adaptometry&#9;57</p>
			<p class="fm-only_fm-toc01"><span class="fm-toc01--part-">Part II </span>Disorders of the Ret&#173;ina and Vitreous<span class="fm-toc--leader-dots-">&#9;</span>59</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;4&#9;</span>Age-&#173;Related Macular Degeneration and Other &#173;<br />Causes of Choroidal Neovascularization<span class="fm-toc--leader-dots-">&#9;</span>61</p>
			<p class="fm-only_fm-toc03">Age-&#173;Related Macular Degeneration&#9;61</p>
			<p class="fm-only_fm-toc04">Ge&#173;ne&#173;tics and AMD&#9;62</p>
			<p class="fm-only_fm-toc04">Nonneovascular AMD&#9;63</p>
			<p class="fm-only_fm-toc04">Neovascular AMD&#9;71</p>
			<p class="fm-only_fm-toc03">Other &#173;Causes of Choroidal Neovascularization&#9;86</p>
			<p class="fm-only_fm-toc04">Ocular Histoplasmosis Syndrome&#9;86</p>
			<p class="fm-only_fm-toc04">Angioid Streaks&#9;87</p>
			<p class="fm-only_fm-toc04">Pathologic Myopia&#9;89</p>
			<p class="fm-only_fm-toc04">Idiopathic CNV and Miscellaneous &#173;Causes of CNV&#9;89</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;5&#9;</span>Ret&#173;i&#173;nal Vascular Disease: Diabetic&#160;Retinopathy<span class="fm-toc--leader-dots-">&#9;</span>91</p>
			<p class="fm-only_fm-toc03">Terminology and Classification&#9;91</p>
			<p class="fm-only_fm-toc04">Diabetes Terminology&#9;91</p>
			<p class="fm-only_fm-toc04">Diabetic Retinopathy Terminology&#9;91</p>
			<p class="fm-only_fm-toc03">Epidemiology of Diabetic Retinopathy&#9;92</p>
			<p class="fm-only_fm-toc03">Pathogenesis of Diabetic Retinopathy&#9;93</p>
			<p class="fm-only_fm-toc03">Recommended Diabetes Mellitus–&#173;Related Ophthalmic <br />Examinations&#9;93</p>
			<p class="fm-only_fm-toc03">Systemic Medical Management of Diabetic Retinopathy&#9;96</p>
			<p class="fm-only_fm-toc03">Abnormalities Associated With Vision Loss From Diabetic <br />Retinopathy&#9;98</p>
			<p class="fm-only_fm-toc03">Nonproliferative Diabetic Retinopathy&#9;99</p>
			<p class="fm-only_fm-toc04">Treatment of Nonproliferative Diabetic Retinopathy&#9;101</p>
			<p class="fm-only_fm-toc03">Proliferative Diabetic Retinopathy&#9;102</p>
			<p class="fm-only_fm-toc04">Management of Proliferative Diabetic Retinopathy <br />and Its Complications&#9;103</p>
			<p class="fm-only_fm-toc03">Diabetic Macular Edema&#9;108</p>
			<p class="fm-only_fm-toc04">Classification of Diabetic Macular Edema&#9;109</p>
			<p class="fm-only_fm-toc04">Treatment of Diabetic Macular Edema&#9;110</p>
			<p class="fm-only_fm-toc03">Cataract Surgery in Patients With Diabetes Mellitus&#9;116</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;6&#9;</span>Ret&#173;i&#173;nal Vascular Diseases Associated <br />With Cardiovascular Disease<span class="fm-toc--leader-dots-">&#9;</span>121</p>
			<p class="fm-only_fm-toc03">Systemic Arterial Hypertension&#9;121</p>
			<p class="fm-only_fm-toc04">Hypertensive Retinopathy&#9;121</p>
			<p class="fm-only_fm-toc04">Hypertensive Choroidopathy&#9;123</p>
			<p class="fm-only_fm-toc04">Hypertensive Optic Neuropathy&#9;123</p>
			<p class="fm-only_fm-toc03">Ret&#173;i&#173;nal Vein Occlusion&#9;125</p>
			<p class="fm-only_fm-toc04">Branch Ret&#173;i&#173;nal Vein Occlusion&#9;126</p>
			<p class="fm-only_fm-toc04">Central Ret&#173;i&#173;nal Vein Occlusion&#9;130</p>
			<p class="fm-only_fm-toc04">Pharmacologic Management of Ret&#173;i&#173;nal Vein Occlusion&#9;135</p>
			<p class="fm-only_fm-toc03">Ocular Ischemic Syndrome and Retinopathy of Carotid <br />Occlusive Disease&#9;138</p>
			<p class="fm-only_fm-toc04">Symptoms and Signs of Ocular Ischemic Syndrome&#9;138</p>
			<p class="fm-only_fm-toc04">Etiology and Course of Ocular Ischemic Syndrome&#9;139</p>
			<p class="fm-only_fm-toc04">Treatment of Ocular Ischemic Syndrome&#9;140</p>
			<p class="fm-only_fm-toc03">Arterial Occlusive Disease&#9;140</p>
			<p class="fm-only_fm-toc04">Capillary Ret&#173;i&#173;nal Arteriole Obstruction (Cotton-&#173;Wool Spots)&#9;140</p>
			<p class="fm-only_fm-toc04">Branch Ret&#173;i&#173;nal Artery Occlusion&#9;141</p>
			<p class="fm-only_fm-toc04">Cilioret&#173;i&#173;nal Artery Occlusion&#9;143</p>
			<p class="fm-only_fm-toc04">Paracentral Acute &#173;Middle Maculopathy&#9;143</p>
			<p class="fm-only_fm-toc04">Central Ret&#173;i&#173;nal Artery Occlusion&#9;143</p>
			<p class="fm-only_fm-toc04">Ophthalmic Artery Occlusion&#9;146</p>
			<p class="fm-only_fm-toc03">Arterial Macroaneurysms&#9;147</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;7&#9;</span>Other Ret&#173;i&#173;nal Vascular Diseases<span class="fm-toc--leader-dots-">&#9;</span>149</p>
			<p class="fm-only_fm-toc03">Sickle Cell Retinopathy&#9;149</p>
			<p class="fm-only_fm-toc04">Nonproliferative Sickle Cell Retinopathy&#9;149</p>
			<p class="fm-only_fm-toc04">Proliferative Sickle Cell Retinopathy&#9;150</p>
			<p class="fm-only_fm-toc04">Other Ocular Abnormalities in Sickle Cell Hemoglobinopathies&#9;154</p>
			<p class="fm-only_fm-toc04">Management of Sickle Cell Retinopathy&#9;154</p>
			<p class="fm-only_fm-toc03">Vasculitis&#9;155</p>
			<p class="fm-only_fm-toc03">Cystoid Macular Edema&#9;156</p>
			<p class="fm-only_fm-toc04">Etiologies of CME&#9;157</p>
			<p class="fm-only_fm-toc04">Incidence of CME&#9;157</p>
			<p class="fm-only_fm-toc04">Treatment of CME&#9;159</p>
			<p class="fm-only_fm-toc03">Coats Disease&#9;159</p>
			<p class="fm-only_fm-toc03">Macular Telangiectasia&#9;161</p>
			<p class="fm-only_fm-toc04">Macular Telangiectasia Type 1&#9;161</p>
			<p class="fm-only_fm-toc04">Macular Telangiectasia Type 2&#9;161</p>
			<p class="fm-only_fm-toc04">Macular Telangiectasia Type 3&#9;164</p>
			<p class="fm-only_fm-toc03">Phakomatoses&#9;165</p>
			<p class="fm-only_fm-toc04">Von Hippel–&#173;Lindau Disease&#9;165</p>
			<p class="fm-only_fm-toc04">Wyburn-&#173;Mason Syndrome&#9;168</p>
			<p class="fm-only_fm-toc04">Ret&#173;i&#173;nal Cavernous Hemangioma&#9;168</p>
			<p class="fm-only_fm-toc03">Radiation Retinopathy&#9;170</p>
			<p class="fm-only_fm-toc03">Valsalva Retinopathy&#9;171</p>
			<p class="fm-only_fm-toc03">Purtscher Retinopathy and Purtscherlike Retinopathy&#9;171</p>
			<p class="fm-only_fm-toc03">Terson Syndrome&#9;173</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;8&#9;</span>Retinopathy of Prematurity<span class="fm-toc--leader-dots-">&#9;</span>175</p>
			<p class="fm-only_fm-toc03">Introduction&#9;175</p>
			<p class="fm-only_fm-toc04">Epidemiology&#9;175</p>
			<p class="fm-only_fm-toc03">Terminology and Classification&#9;175</p>
			<p class="fm-only_fm-toc03">Pathophysiology of ROP&#9;180</p>
			<p class="fm-only_fm-toc04">Natu&#173;ral Course&#9;181</p>
			<p class="fm-only_fm-toc04">Associated Conditions and Late Sequelae&#9;181</p>
			<p class="fm-only_fm-toc03">Screening Recommendations&#9;182</p>
			<p class="fm-only_fm-toc04">Screening Criteria&#9;182</p>
			<p class="fm-only_fm-toc04">Screening Intervals&#9;183</p>
			<p class="fm-only_fm-toc04">Fundus Photographic Screening of ROP&#9;184</p>
			<p class="fm-only_fm-toc03">Prevention and Risk &#173;Factors&#9;184</p>
			<p class="fm-only_fm-toc03">Treatment&#9;185</p>
			<p class="fm-only_fm-toc04">&#173;Laser and Cryoablation Surgery&#9;185</p>
			<p class="fm-only_fm-toc04">Anti-&#173;VEGF Drugs&#9;186</p>
			<p class="fm-only_fm-toc04">Vitrectomy and Scleral Buckling Surgery&#9;187</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;9&#9;</span>Choroidal Disease<span class="fm-toc--leader-dots-">&#9;</span>189</p>
			<p class="fm-only_fm-toc03">Central Serous Chorioretinopathy&#9;189</p>
			<p class="fm-only_fm-toc04">Demographics&#9;189</p>
			<p class="fm-only_fm-toc04">Imaging&#9;191</p>
			<p class="fm-only_fm-toc04">Differential Diagnosis&#9;193</p>
			<p class="fm-only_fm-toc04">Treatment&#9;194</p>
			<p class="fm-only_fm-toc03">Choroidal Perfusion Abnormalities&#9;194</p>
			<p class="fm-only_fm-toc04">Arteritic Disease&#9;195</p>
			<p class="fm-only_fm-toc04">Nonarteritic Disease&#9;195</p>
			<p class="fm-only_fm-toc04">Choriocapillaris Blood Flow Abnormalities&#9;198</p>
			<p class="fm-only_fm-toc04">Increased Venous Pressure&#9;198</p>
			<p class="fm-only_fm-toc03">Age-&#173;Related Choroidal Atrophy&#9;200</p>
			<p class="fm-only_fm-toc03">Choroidal Folds&#9;200</p>
			<p class="fm-only_fm-toc03">Choroidal Hemangiomas&#9;202</p>
			<p class="fm-only_fm-toc03">Uveal Effusion Syndrome&#9;203</p>
			<p class="fm-only_fm-toc03">Bilateral Diffuse Uveal Melanocytic Proliferation&#9;204</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;10&#9;</span>Myopia and Pathologic Myopia<span class="fm-toc--leader-dots-">&#9;</span>207</p>
			<p class="fm-only_fm-toc03">Prevention&#9;207</p>
			<p class="fm-only_fm-toc03">The Ret&#173;ina&#9;208</p>
			<p class="fm-only_fm-toc04">Bruch Membrane&#9;210</p>
			<p class="fm-only_fm-toc04">Choroidal Neovascularization&#9;211</p>
			<p class="fm-only_fm-toc04">The Choroid in Pathologic Myopia&#9;212</p>
			<p class="fm-only_fm-toc03">The Sclera&#9;216</p>
			<p class="fm-only_fm-toc03">The Optic Nerve&#9;217</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;11&#9;</span>Focal and Diffuse Choroidal and&#160;Ret&#173;i&#173;nal <br />Inflammation<span class="fm-toc--leader-dots-">&#9;</span>219</p>
			<p class="fm-only_fm-toc03">Noninfectious Ret&#173;i&#173;nal and Choroidal Inflammation&#9;219</p>
			<p class="fm-only_fm-toc04">White Dot Syndromes&#9;219</p>
			<p class="fm-only_fm-toc04">Chorioret&#173;i&#173;nal Autoimmune Conditions&#9;229</p>
			<p class="fm-only_fm-toc04">Sympathetic Ophthalmia&#9;233</p>
			<p class="fm-only_fm-toc04">Uveitis Masquerade: Intraocular Lymphoma&#9;233</p>
			<p class="fm-only_fm-toc03">Infectious Ret&#173;i&#173;nal and Choroidal Inflammation&#9;235</p>
			<p class="fm-only_fm-toc04">Cytomegalovirus Retinitis&#9;235</p>
			<p class="fm-only_fm-toc04">Non-&#173;CMV Necrotizing Herpetic Retinitis&#9;236</p>
			<p class="fm-only_fm-toc04">Endogenous Bacterial Endophthalmitis&#9;237</p>
			<p class="fm-only_fm-toc04">Fungal Endophthalmitis&#9;239</p>
			<p class="fm-only_fm-toc04">Tuberculosis&#9;240</p>
			<p class="fm-only_fm-toc04">Syphilitic Chorioretinitis&#9;241</p>
			<p class="fm-only_fm-toc04">Cat-&#173;Scratch Disease&#9;242</p>
			<p class="fm-only_fm-toc04">Toxoplasmic Retinochoroiditis&#9;243</p>
			<p class="fm-only_fm-toc04">Toxocariasis&#9;244</p>
			<p class="fm-only_fm-toc04">Lyme Disease&#9;245</p>
			<p class="fm-only_fm-toc04">Diffuse Unilateral Subacute Neuroretinitis&#9;246</p>
			<p class="fm-only_fm-toc04">West Nile Virus Chorioretinitis&#9;246</p>
			<p class="fm-only_fm-toc04">Zika Virus Chorioretinitis&#9;247</p>
			<p class="fm-only_fm-toc04">Ebola Virus Panuveitis&#9;247</p>
			<p class="fm-only_fm-toc04">Chikungunya Virus Retinitis&#9;247</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;12&#9;</span>Congenital and Stationary Ret&#173;i&#173;nal&#160;Disease<span class="fm-toc--leader-dots-">&#9;</span>249</p>
			<p class="fm-only_fm-toc03">Color Vision (Cone System) Abnormalities&#9;249</p>
			<p class="fm-only_fm-toc04">Congenital Color Deficiency&#9;249</p>
			<p class="fm-only_fm-toc03">Night Vision (Rod System) Abnormalities&#9;251</p>
			<p class="fm-only_fm-toc04">Congenital Night-&#173;Blinding Disorders With Normal Fundi&#9;251</p>
			<p class="fm-only_fm-toc04">Congenital Night-&#173;Blinding Disorders With Fundus Abnormality&#9;252</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;13&#9;</span>Hereditary Ret&#173;i&#173;nal and Choroidal&#160;Dystrophies<span class="fm-toc--leader-dots-">&#9;</span>255</p>
			<p class="fm-only_fm-toc03">Classification&#9;255</p>
			<p class="fm-only_fm-toc03">General Diagnostic Considerations&#9;258</p>
			<p class="fm-only_fm-toc03">General Ge&#173;ne&#173;tic Considerations&#9;259</p>
			<p class="fm-only_fm-toc03">General Management Considerations&#9;259</p>
			<p class="fm-only_fm-toc03">Diffuse Dystrophies&#9;261</p>
			<p class="fm-only_fm-toc04">Diffuse Photoreceptor Dystrophies&#9;261</p>
			<p class="fm-only_fm-toc04">Choroidal Dystrophies&#9;267</p>
			<p class="fm-only_fm-toc03">Macular Dystrophies&#9;269</p>
			<p class="fm-only_fm-toc04">Stargardt Disease&#9;269</p>
			<p class="fm-only_fm-toc04">Best Disease or Best Vitelliform Dystrophy&#9;271</p>
			<p class="fm-only_fm-toc04">Adult-&#173;Onset Vitelliform Lesions&#9;272</p>
			<p class="fm-only_fm-toc04">Early-&#173;Onset “Drusenoid” Macular Dystrophies&#9;273</p>
			<p class="fm-only_fm-toc04">Pattern Dystrophies&#9;276</p>
			<p class="fm-only_fm-toc04">Aty&#173;pi&#173;cal and “Occult” Macular Dystrophies&#9;277</p>
			<p class="fm-only_fm-toc03">Inner Ret&#173;i&#173;nal Dystrophies&#9;278</p>
			<p class="fm-only_fm-toc04">X-&#173;Linked Retinoschisis&#9;278</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;14&#9;</span>Ret&#173;i&#173;nal Degenerations Associated <br />With Systemic Disease<span class="fm-toc--leader-dots-">&#9;</span>281</p>
			<p class="fm-only_fm-toc03">Ret&#173;i&#173;nal Degeneration With Systemic Involvement&#9;281</p>
			<p class="fm-only_fm-toc04">Infantile-&#173;Onset to Early Childhood–&#173;Onset Syndromes&#9;281</p>
			<p class="fm-only_fm-toc04">Bardet-&#173;Biedl Syndrome&#9;281</p>
			<p class="fm-only_fm-toc04">Hearing Loss and Pigmentary Retinopathy: Usher Syndrome&#9;284</p>
			<p class="fm-only_fm-toc04">Neuromuscular Disorders&#9;285</p>
			<p class="fm-only_fm-toc04">Other Organ System Disorders&#9;285</p>
			<p class="fm-only_fm-toc04">Paraneoplastic and Autoimmune Retinopathies&#9;286</p>
			<p class="fm-only_fm-toc03">Metabolic Diseases&#9;288</p>
			<p class="fm-only_fm-toc04">Albinism&#9;288</p>
			<p class="fm-only_fm-toc04">Central Ner&#173;vous System Metabolic Abnormalities&#9;288</p>
			<p class="fm-only_fm-toc04">Amino Acid Disorders&#9;293</p>
			<p class="fm-only_fm-toc04">Mitochondrial Disorders&#9;293</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;15&#9;</span>Systemic Drug-&#173;Induced Ret&#173;i&#173;nal&#160;Toxicity<span class="fm-toc--leader-dots-">&#9;</span>295</p>
			<p class="fm-only_fm-toc03">Drugs Causing Abnormalities of the Ret&#173;i&#173;nal Pigment Epithelium/<br />Photoreceptor Complex&#9;295</p>
			<p class="fm-only_fm-toc04">Chloroquine Derivatives&#9;295</p>
			<p class="fm-only_fm-toc04">Phenothiazines&#9;297</p>
			<p class="fm-only_fm-toc04">Miscellaneous Medi&#173;cations&#9;298</p>
			<p class="fm-only_fm-toc03">Drugs Causing Occlusive Retinopathy or Microvasculopathy&#9;300</p>
			<p class="fm-only_fm-toc03">Drugs Causing Ganglion Cell and Optic Nerve Toxicity&#9;301</p>
			<p class="fm-only_fm-toc03">Drugs Causing Macular Edema&#9;301</p>
			<p class="fm-only_fm-toc03">Drugs Causing Crystalline Retinopathy&#9;302</p>
			<p class="fm-only_fm-toc03">Drugs Causing Abnormalities in Color Vision and <br />Electroretinography&#9;304</p>
			<p class="fm-only_fm-toc03">Miscellaneous Drugs Causing Ocular Toxicities&#9;305</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;16&#9;</span>Ret&#173;i&#173;nal Detachment and Predisposing Lesions<span class="fm-toc--leader-dots-">&#9;</span>307</p>
			<p class="fm-only_fm-toc03">Posterior Vitreous Detachment&#9;307</p>
			<p class="fm-only_fm-toc04">Examination and Management of Posterior Vitreous Detachment&#9;309</p>
			<p class="fm-only_fm-toc03">Lesions That Predispose Eyes to Ret&#173;i&#173;nal Detachment&#9;309</p>
			<p class="fm-only_fm-toc04">Lattice Degeneration&#9;309</p>
			<p class="fm-only_fm-toc04">Vitreoret&#173;i&#173;nal Tufts&#9;311</p>
			<p class="fm-only_fm-toc04">Meridional Folds, Enclosed Ora Bays, and Peripheral Ret&#173;i&#173;nal <br />Excavations&#9;312</p>
			<p class="fm-only_fm-toc03">Lesions That Do Not Predispose Eyes to Ret&#173;i&#173;nal Detachment&#9;313</p>
			<p class="fm-only_fm-toc04">Paving-&#173;Stone Degeneration&#9;313</p>
			<p class="fm-only_fm-toc04">Ret&#173;i&#173;nal Pigment Epithelial Hyperplasia&#9;313</p>
			<p class="fm-only_fm-toc04">Ret&#173;i&#173;nal Pigment Epithelial Hypertrophy&#9;314</p>
			<p class="fm-only_fm-toc04">Peripheral Cystoid Degeneration&#9;314</p>
			<p class="fm-only_fm-toc03">Ret&#173;i&#173;nal Breaks&#9;314</p>
			<p class="fm-only_fm-toc04">Traumatic Breaks&#9;315</p>
			<p class="fm-only_fm-toc04">Trauma in Young Eyes&#9;316</p>
			<p class="fm-only_fm-toc03">Prophylactic Treatment of Ret&#173;i&#173;nal Breaks&#9;317</p>
			<p class="fm-only_fm-toc04">Symptomatic Ret&#173;i&#173;nal Breaks&#9;318</p>
			<p class="fm-only_fm-toc04">Asymptomatic Ret&#173;i&#173;nal Breaks&#9;318</p>
			<p class="fm-only_fm-toc04">Lattice Degeneration&#9;319</p>
			<p class="fm-only_fm-toc04">Aphakia and Pseudophakia&#9;319</p>
			<p class="fm-only_fm-toc04">Fellow Eye in Patients With Ret&#173;i&#173;nal Detachment&#9;319</p>
			<p class="fm-only_fm-toc04">Subclinical Ret&#173;i&#173;nal Detachment&#9;319</p>
			<p class="fm-only_fm-toc03">Ret&#173;i&#173;nal Detachment&#9;320</p>
			<p class="fm-only_fm-toc04">Rhegmatogenous Ret&#173;i&#173;nal Detachment&#9;320</p>
			<p class="fm-only_fm-toc04">Tractional Ret&#173;i&#173;nal Detachment&#9;325</p>
			<p class="fm-only_fm-toc04">Exudative Ret&#173;i&#173;nal Detachment&#9;325</p>
			<p class="fm-only_fm-toc03">Differential Diagnosis of Ret&#173;i&#173;nal Detachment&#9;326</p>
			<p class="fm-only_fm-toc04">Retinoschisis&#9;326</p>
			<p class="fm-only_fm-toc04">Differentiation of Retinoschisis From Rhegmatogenous <br />Ret&#173;i&#173;nal Detachment&#9;327</p>
			<p class="fm-only_fm-toc03">Macular Lesions Associated With Ret&#173;i&#173;nal Detachment&#9;328</p>
			<p class="fm-only_fm-toc04">Optic Pit Maculopathy&#9;328</p>
			<p class="fm-only_fm-toc04">Macular Holes in High Myopia&#9;330</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;17&#9;</span>Diseases of the Vitreous and&#160;Vitreoret&#173;i&#173;nal Interface<span class="fm-toc--leader-dots-">&#9;</span>331</p>
			<p class="fm-only_fm-toc03">Posterior Vitreous Detachment&#9;331</p>
			<p class="fm-only_fm-toc04">Epiret&#173;i&#173;nal Membranes&#9;332</p>
			<p class="fm-only_fm-toc04">Vitreomacular Traction Diseases&#9;336</p>
			<p class="fm-only_fm-toc04">Idiopathic Macular Holes&#9;337</p>
			<p class="fm-only_fm-toc03">Developmental Abnormalities&#9;340</p>
			<p class="fm-only_fm-toc04">Tunica Vasculosa Lentis&#9;340</p>
			<p class="fm-only_fm-toc04">Prepapillary Vascular Loops&#9;341</p>
			<p class="fm-only_fm-toc04">Per&#173;sis&#173;tent Fetal Vasculature&#9;341</p>
			<p class="fm-only_fm-toc03">Hereditary Hyaloideoretinopathies With Optically Empty Vitreous: <br />Wagner and Stickler Syndromes&#9;342</p>
			<p class="fm-only_fm-toc03">Familial Exudative Vitreoretinopathy&#9;343</p>
			<p class="fm-only_fm-toc03">Vitreous Opacities&#9;344</p>
			<p class="fm-only_fm-toc04">Vitreous Degeneration and Detachment Associated Opacities <br />(“Floaters”)&#9;344</p>
			<p class="fm-only_fm-toc04">Asteroid Hyalosis&#9;346</p>
			<p class="fm-only_fm-toc04">Vitreous Hemorrhage&#9;347</p>
			<p class="fm-only_fm-toc04">Pigment Granules&#9;348</p>
			<p class="fm-only_fm-toc04">Cholesterolosis&#9;348</p>
			<p class="fm-only_fm-toc04">Amyloidosis&#9;348</p>
			<p class="fm-only_fm-toc03">Vitreous Abnormalities Secondary to Surgery&#9;349</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;18&#9;</span>Posterior Segment Manifestations of Trauma<span class="fm-toc--leader-dots-">&#9;</span>351</p>
			<p class="fm-only_fm-toc03">Evaluation of the Patient &#173;After Ocular Trauma&#9;351</p>
			<p class="fm-only_fm-toc03">Blunt Trauma Without Break in Eye Wall&#9;353</p>
			<p class="fm-only_fm-toc04">Commotio Ret&#173;i&#173;nae&#9;353</p>
			<p class="fm-only_fm-toc04">Choroidal Rupture&#9;354</p>
			<p class="fm-only_fm-toc04">Posttraumatic Macular Hole&#9;355</p>
			<p class="fm-only_fm-toc04">Vitreous Hemorrhage&#9;357</p>
			<p class="fm-only_fm-toc04">Traumatic Chorioret&#173;i&#173;nal Disruption (Ret&#173;i&#173;nal Sclopetaria)&#9;357</p>
			<p class="fm-only_fm-toc03">Open-&#173;Globe Injuries&#9;358</p>
			<p class="fm-only_fm-toc04">Scleral Rupture&#9;358</p>
			<p class="fm-only_fm-toc04">Lacerating and Penetrating Injuries&#9;358</p>
			<p class="fm-only_fm-toc04">Perforating Injuries&#9;358</p>
			<p class="fm-only_fm-toc04">Surgical Management&#9;359</p>
			<p class="fm-only_fm-toc04">Intraocular Foreign Bodies&#9;360</p>
			<p class="fm-only_fm-toc03">Posttraumatic Endophthalmitis&#9;362</p>
			<p class="fm-only_fm-toc03">Prognostication of Globe Injuries&#9;363</p>
			<p class="fm-only_fm-toc03">Sympathetic Ophthalmia&#9;364</p>
			<p class="fm-only_fm-toc03">Avulsion of the Optic Nerve Head&#9;365</p>
			<p class="fm-only_fm-toc03">Abusive Head Trauma&#9;365</p>
			<p class="fm-only_fm-toc03">Photic Damage&#9;367</p>
			<p class="fm-only_fm-toc04">Solar Retinopathy&#9;367</p>
			<p class="fm-only_fm-toc04">Phototoxicity From Ophthalmic Instrumentation&#9;368</p>
			<p class="fm-only_fm-toc04">Occupational Light Toxicity&#9;369</p>
			<p class="fm-only_fm-toc04">Handheld Laser-&#173;Pointer Injury&#9;369</p>
			<p class="fm-only_fm-toc01"><span class="fm-toc01--part-">Part III </span>Selected Therapeutic Topics<span class="fm-toc--leader-dots-">&#9;</span>371</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;19&#9;</span>&#173;Laser Therapy for Posterior Segment Diseases<span class="fm-toc--leader-dots-">&#9;</span>373</p>
			<p class="fm-only_fm-toc03">Basic Princi&#173;ples of Photocoagulation&#9;373</p>
			<p class="fm-only_fm-toc04">Choice of &#173;Laser Wavelength&#9;373</p>
			<p class="fm-only_fm-toc04">Practical Aspects of &#173;Laser Photocoagulation&#9;375</p>
			<p class="fm-only_fm-toc04">Complications of Photocoagulation&#9;378</p>
			<p class="fm-only_fm-toc03">Transpupillary Thermotherapy&#9;380</p>
			<p class="fm-only_fm-toc03">Photodynamic Therapy&#9;380</p>
			<p class="fm-only_fm-toc04">Complications of Photodynamic Therapy&#9;380</p>
			<p class="fm-only_fm-toc02"><span class="fm-toc02--num-">&#9;20&#9;</span>Vitreoret&#173;i&#173;nal Surgery and Intravitreal Injections<span class="fm-toc--leader-dots-">&#9;</span>381</p>
			<p class="fm-only_fm-toc03">Pars Plana Vitrectomy&#9;381</p>
			<p class="fm-only_fm-toc03">Vitrectomy for Selected Macular Diseases&#9;382</p>
			<p class="fm-only_fm-toc04">Macular Epiret&#173;i&#173;nal Membranes&#9;382</p>
			<p class="fm-only_fm-toc04">Vitreomacular Traction Diseases&#9;382</p>
			<p class="fm-only_fm-toc04">Submacular Hemorrhage&#9;385</p>
			<p class="fm-only_fm-toc03">Vitrectomy for Vitreous Opacities&#9;386</p>
			<p class="fm-only_fm-toc03">Vitrectomy for Complications of Diabetic Retinopathy&#9;386</p>
			<p class="fm-only_fm-toc04">Vitreous Hemorrhage&#9;386</p>
			<p class="fm-only_fm-toc04">Diabetic Tractional Ret&#173;i&#173;nal Detachment&#9;387</p>
			<p class="fm-only_fm-toc04">Diabetic Macular Edema&#9;388</p>
			<p class="fm-only_fm-toc03">Vitrectomy for Posterior Segment Complications of Anterior <br />Segment Surgery&#9;388</p>
			<p class="fm-only_fm-toc04">Postoperative Endophthalmitis&#9;388</p>
			<p class="fm-only_fm-toc04">Retained Lens Fragments &#173;After Phacoemulsification&#9;391</p>
			<p class="fm-only_fm-toc04">Posteriorly Dislocated Intraocular Lenses&#9;393</p>
			<p class="fm-only_fm-toc04">Cystoid Macular Edema&#9;393</p>
			<p class="fm-only_fm-toc04">Suprachoroidal Hemorrhage&#9;394</p>
			<p class="fm-only_fm-toc04">Needle Penetration of the Globe&#9;395</p>
			<p class="fm-only_fm-toc03">Rhegmatogenous Ret&#173;i&#173;nal Detachment Surgery&#9;396</p>
			<p class="fm-only_fm-toc04">Techniques for Surgical Repair of Ret&#173;i&#173;nal Detachments&#9;397</p>
			<p class="fm-only_fm-toc04">Outcomes Following Ret&#173;i&#173;nal Reattachment Surgery&#9;401</p>
			<p class="fm-only_fm-toc03">Complications of Pars Plana Vitrectomy&#9;402</p>
			<p class="fm-only_fm-toc03">Intravitreal Injections&#9;403</p>
			<p class="fm-only_fm-toc-endmatter-first">Basic Texts&#9;405</p>
			<p class="fm-only_fm-toc03">Related Acad&#173;emy Materials&#9;407</p>
			<p class="fm-only_fm-toc03">Requesting Continuing Medical Education Credit&#9;409</p>
			<p class="fm-only_fm-toc03">Study Questions&#9;411</p>
			<p class="fm-only_fm-toc03">Answer Sheet for Section&#160;12 Study Questions&#9;421</p>
			<p class="fm-only_fm-toc03">Answers&#9;423</p>
			<p class="fm-only_fm-toc03">Index&#9;431</p>
		</div>
		<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
			<p class="page-elements_rhv"> <span class="rh-bullet"></span> General Introduction</p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer019" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-1" src="Operator_BCSC1819_S12_C00FM_pi-xviii_2P-web-resources/image/qrcode_s12_landing.jpg" alt="" />
			</div>
		</div>
		<div id="_idContainer020" class="Basic-Text-Frame">
			<p class="fm-only_fm-h2_QR">Videos</p>
		</div>
		<div id="_idContainer021" class="Basic-Text-Frame">
			<p class="fm-only_fm-h2_QR">Activities</p>
		</div>
	</body>
</html>
